{"name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","slug":"cliniques-universitaires-saint-luc-universit-catholique-de-louvain","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Immunotherapeutic Agent","genericName":"Immunotherapeutic Agent","slug":"immunotherapeutic-agent","indication":"Other","status":"phase_3"},{"name":"patients with sunitinib or pazopanib","genericName":"patients with sunitinib or pazopanib","slug":"patients-with-sunitinib-or-pazopanib","indication":"Other","status":"marketed"},{"name":"Aerosoltherapy","genericName":"Aerosoltherapy","slug":"aerosoltherapy","indication":"Other","status":"phase_1"},{"name":"Randomisation to mepolizumab","genericName":"Randomisation to mepolizumab","slug":"randomisation-to-mepolizumab","indication":"Other","status":"marketed"},{"name":"Theravac","genericName":"Theravac","slug":"theravac","indication":"Other","status":"phase_1"},{"name":"biomarker","genericName":"biomarker","slug":"biomarker","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"O.M.T","genericName":"O.M.T","slug":"o-m-t","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"},{"name":"Blood samples for DOAC measurement","genericName":"Blood samples for DOAC measurement","slug":"blood-samples-for-doac-measurement","indication":"Therapeutic drug monitoring of direct oral anticoagulants","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Povidone-Iodine 10%","genericName":"Povidone-Iodine 10%","slug":"povidone-iodine-10","indication":"Prevention of infection in minor cuts and burns","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Randomisation to omalizumab","genericName":"Randomisation to omalizumab","slug":"randomisation-to-omalizumab","indication":"Moderate-to-severe allergic asthma","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"exenatide (Byetta)","genericName":"exenatide (Byetta)","slug":"exenatide-byetta","indication":"Type 2 diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"Immunotherapeutic Agent","genericName":"Immunotherapeutic Agent","slug":"immunotherapeutic-agent","phase":"phase_3","mechanism":"An immunotherapeutic agent that activates or modulates the immune system to enhance anti-tumor or anti-disease responses.","indications":[],"catalyst":""},{"name":"O.M.T","genericName":"O.M.T","slug":"o-m-t","phase":"phase_3","mechanism":"O.M.T is a medication used to treat atrial fibrillation.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"patients with sunitinib or pazopanib","genericName":"patients with sunitinib or pazopanib","slug":"patients-with-sunitinib-or-pazopanib","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aerosoltherapy","genericName":"Aerosoltherapy","slug":"aerosoltherapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Blood samples for DOAC measurement","genericName":"Blood samples for DOAC measurement","slug":"blood-samples-for-doac-measurement","phase":"marketed","mechanism":"This is a laboratory testing service that measures direct oral anticoagulant (DOAC) concentrations in blood samples.","indications":["Therapeutic drug monitoring of direct oral anticoagulants","Assessment of DOAC compliance and adherence","Perioperative management of anticoagulated patients","Evaluation of bleeding or thrombotic events in DOAC-treated patients"],"catalyst":""},{"name":"Povidone-Iodine 10%","genericName":"Povidone-Iodine 10%","slug":"povidone-iodine-10","phase":"marketed","mechanism":"Small molecule","indications":["Prevention of infection in minor cuts and burns"],"catalyst":""},{"name":"Randomisation to mepolizumab","genericName":"Randomisation to mepolizumab","slug":"randomisation-to-mepolizumab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Randomisation to omalizumab","genericName":"Randomisation to omalizumab","slug":"randomisation-to-omalizumab","phase":"marketed","mechanism":"Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing its interaction with high-affinity IgE receptors on mast cells and basophils.","indications":["Moderate-to-severe allergic asthma","Chronic spontaneous urticaria","Nasal polyposis with eosinophilic granulomatosis with polyangiitis (EGPA)"],"catalyst":""},{"name":"Theravac","genericName":"Theravac","slug":"theravac","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"biomarker","genericName":"biomarker","slug":"biomarker","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"exenatide (Byetta)","genericName":"exenatide (Byetta)","slug":"exenatide-byetta","phase":"marketed","mechanism":"Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQd2QtMS1pZkY2RXQtekE3blBxNEtXdUVaUWo2b3otRENBdWpwVEhoSm1pRjJ2S0NYVkNhbTNybzB2VnUzMjBKRzc3MmdsNzJ2NW5uUjEtOGRmNnh3a04tY2EwZmNxeFlIVHEtRWVnZ2Rvd1ZiRnNnZHpEV0NDaU1Xbms1dzlUWlUwcXc0QlVCS1N6ZVp4UnBz?oc=5","date":"2026-01-29","type":"pipeline","source":"European Medical Journal","summary":"Evolving Prostate Cancer Therapy: Bertrand Tombal - European Medical Journal","headline":"Evolving Prostate Cancer Therapy: Bertrand Tombal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxORFcweWlpUm9vZnhZM1F1SnBzMEVldVBMcW5RTV9WV2dRRjJKV3p2dnFqN2xRWnRWVkthRkpxTGdxTkd2bThrRngwaWgzemJ1YzI3R0xVR2tGLVdONGNjQ2lEU1pMazZUS2RDbnNTTlVkNkJXRkp4b3diUlhYQkhkdEZzbTBiRDF2R0pTV1ZNN2J0a0NmU3l0UkQzdnJjTjl1R2c?oc=5","date":"2025-11-21","type":"pipeline","source":"European Medical Journal","summary":"Fast Five: Bertrand Tombal on Genitourinary Cancer Updates - European Medical Journal","headline":"Fast Five: Bertrand Tombal on Genitourinary Cancer Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNVUycW1weTBvQklFQXhnb2tHSTl6cnh1NVBvdkI2bnRsNnF6NmJDVHljczdSVXpIaUE5cW92SjJuWUxoa0lRZHBqVDRyMHVDaGs4ZXZwRUtEdE5qcFJ3bnRQbVdNUnhiZlBlV1ZLbW5MWVN5XzVualVIU2tuYzBBRnZGdkNybUN6cWZReFFDM19LRE5jUmJnZW9B?oc=5","date":"2025-10-24","type":"trial","source":"Frontiers","summary":"Implementation of Medication Review Type 2a in Community Pharmacies: A Longitudinal Survey Study - Frontiers","headline":"Implementation of Medication Review Type 2a in Community Pharmacies: A Longitudinal Survey Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRVVjRWRybkZMMjFzZGtEZE1Pd2ZYVjBwQjBaZFJJdlVxdHJxZU1BaXY3aGJSRjNER3hzWm9FaE5FdlJmUXBhWmlEeXQ0NXRCTHRFR2RxQV9mS3FZTzdLUmVzZG5SU05mMXY5eEk5U1NTOGZETDJDbm9oQVVGTkNjeG85YkUteUUwSm94ZWVKb3lldE10VklTZ3B1cEtCcFJKd1NpYVNhb3VIUzQ?oc=5","date":"2025-08-14","type":"pipeline","source":"European Medical Journal","summary":"Paradigm Changes in Prostate Cancer Management in Recent Years - European Medical Journal","headline":"Paradigm Changes in Prostate Cancer Management in Recent Years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE54NWNSdzhVNnBzVjNSTy1TaVFGZDVkNjE4c3VrVWc0RTZjZEthUGgtQk1xWmFNeFMyUncwcEhmVWZRSWNEZ2M4NW9nWDdTWTNmdHBTUHREVWFPTWdTeVNpQkloY0ltcTVmeFNz?oc=5","date":"2024-10-09","type":"pipeline","source":"Wiley Online Library","summary":"Clinical relevance of paramagnetic rim lesion heterogeneity in multiple sclerosis - Wiley Online Library","headline":"Clinical relevance of paramagnetic rim lesion heterogeneity in multiple sclerosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNaVMxZDh5Y3RHLVdWSW1rRXh3Rm84UklDcjRvNVk2RUl0dXFFT0FoV0VqNDYzQ3EwdmVuLWFrZHRmNDJIbWNhblp0Y2pGWU1BVlNpd19sbHEyNXR3OXc0cFFNVVRZa2JQcGhCZUpqTVVWWlVzTkFiUlBFWWJIWE1jNV9oeWVpSlF5ekM3dHhuTVRoX0dUdWM4Uk5lOHpPVWNWWDAxcHI0RFg0QzdGdWU5VlVCb2N3WnZqcmFpcm1FMk9pZnFyWXg4UWluVWUwd0M3RFFENVF0ZVczY0gzRFJRcko3aXA5REdobEstZ1ZlZ21BZlNsU3JRUUpVRzF2b2FyVmpiTnBZbkFOSzJYdUdFczhCR1lDN3d5alFOVzRUal83TDdMU2NmNkhIcDYzb00?oc=5","date":"2024-01-17","type":"deal","source":"Business Wire","summary":"PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project - Business Wire","headline":"PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Thera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPSmJTY3VBRE1MelM4QWZmQjBSYXVjdmo5SG5ubm9Dc3JsOFFmY0Y0WE9WSmExTzk5T2MxZVVtWHJ6aThJVlkzNjFya2l3R1hZVVBrZHd0VmM1ektwT1NNcmJYeEFLVFh4M0YtaDhMODFnWjhNb09meTU0VFpjZ1J5ZUpreVBfVDBKWkdId0VvVHhTMGt5TGc?oc=5","date":"2023-03-08","type":"pipeline","source":"OncLive","summary":"Dr. Tombal on Darolutamide Monotherapy in Newly Diagnosed mHSPC - OncLive","headline":"Dr. Tombal on Darolutamide Monotherapy in Newly Diagnosed mHSPC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE43aXNsaUxsR1I1WGNlTVhYZERhVURVa0xiVmF4bXYzNktJTzN5OEEtX2IzRW9PWFhzX1BGMHRUNlJ2aXYtU0JSLXNMdWtIZ2NHOHhqX1loNWVtbDQ?oc=5","date":"2021-09-28","type":"pipeline","source":"EurekAlert!","summary":"New radionuclide therapy identified for HER2-positive breast cancer patients - EurekAlert!","headline":"New radionuclide therapy identified for HER2-positive breast cancer patients - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9Lb3ZoUGUzRzFfRzBsX3loRWFPVlM3Mng1WlBrRlNYU2dQbHIwc182U2ZMeHVkOTlEU1JrLUUxRXBnOEl1LTBCeUpFWU5fSlR4OWdYWkRGT00ySmVwb1VZ?oc=5","date":"2021-01-12","type":"pipeline","source":"nature.com","summary":"Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients - nature.com","headline":"Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in ob","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOS01vUDVZczM2Q21vUHFqZHF6WVJMNmRPTTA0cTJWQTlabXpkX085TDBRZ2dHTDVBUm5QeWlMNUd0c0tKeHNRelVCTVl3czZtQlJyQkU4bVk3Z0Y5elNqOHlON0JaMU5FeExncy1Cc2thQUFyeVltc3dtQ19kSkJ6MURIUS1qcnhNaGJsUFhVa2hvQQ?oc=5","date":"2006-05-01","type":"pipeline","source":"Hospital Pharmacy Europe","summary":"Immunosuppression in kidney/pancreas transplant - Hospital Pharmacy Europe","headline":"Immunosuppression in kidney/pancreas transplant","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_3":2,"marketed":6,"phase_1":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}